In preclinical models of PDAC and melanoma, PRMT1 inhibitors combined with anti-PD-1 or anti-PD-L1 antibodies increased CD8+ T cell infiltration, suppressed tumor growth, and partially reversed resistance to ICB therapy [459, 605, 606]. Here, PRMT1 is linked to neoplasm.